Hereditary angioedema: how to approach it at the emergency department?

ABSTRACT Angioedema attacks are common causes of emergency care, and due to the potential for severity, it is important that professionals who work in these services know their causes and management. The mechanisms involved in angioedema without urticaria may be histamine- or bradykinin-mediated. The most common causes of histamine-mediated angioedema are foods, medications, insect sting and idiopathic. When the mediator is bradykinin, the triggers are angiotensin-converting enzyme inhibitors and factors related to acquired angioedema with deficiency of C1-inhibitor or hereditary angioedema, which are less common, but very important because of the possibility of fatal outcome. Hereditary angioedema is a rare disease characterized by attacks of edema that affect the subcutaneous tissue and mucous membranes of various organs, manifesting mainly by angioedema and abdominal pain. This type of angioedema does not respond to the usual treatment with epinephrine, antihistamines and corticosteroids. Thus, if not identified and treated appropriately, these patients have an estimated risk of mortality from laryngeal edema of 25% to 40%. Hereditary angioedema treatment has changed dramatically in recent years with the development of new and efficient drugs for attack management: plasma-derived C1 inhibitor, recombinant human C1-inhibitor, bradykinin B2 receptor antagonist (icatibant), and the kallikrein inhibitor (ecallantide). In Brazil, plasma-derived C1 inhibitor and icatibant have already been approved for use. Proper management of these patients in the emergency department avoids unnecessary surgery and, especially, fatal outcomes.

[1]  R. Senter,et al.  Lanadelumab Injection Treatment For The Prevention Of Hereditary Angioedema (HAE): Design, Development And Place In Therapy , 2019, Drug design, development and therapy.

[2]  I. Braenne,et al.  Hereditary angioedema cosegregating with a novel kininogen 1 gene mutation changing the N‐terminal cleavage site of bradykinin , 2019, Allergy.

[3]  A. Grumach,et al.  Assessment on hereditary angioedema burden of illness in Brazil: A patient perspective. , 2019, Allergy and asthma proceedings.

[4]  M. Cugno,et al.  Angioedema and emergency medicine: From pathophysiology to diagnosis and treatment. , 2019, European journal of internal medicine.

[5]  M. Vlková,et al.  Treatment of Hereditary Angioedema Attacks with Icatibant and Recombinant C1 Inhibitor During Pregnancy , 2018, Journal of Clinical Immunology.

[6]  T. Zuberbier,et al.  The EAACI/GA²LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria , 2018, Allergy.

[7]  A. Maetzel,et al.  Epidemiology of Bradykinin-mediated angioedema: a systematic investigation of epidemiological studies , 2018, Orphanet Journal of Rare Diseases.

[8]  I. Braenne,et al.  Hereditary angioedema with a mutation in the plasminogen gene , 2018, Allergy.

[9]  M. Margaglione,et al.  Mutation of the angiopoietin‐1 gene (ANGPT1) associates with a new type of hereditary angioedema , 2017, The Journal of allergy and clinical immunology.

[10]  C. Buchwald,et al.  Dipeptidyl Peptidase-4 Inhibitor Induced Angioedema - An Overlooked Adverse Drug Reaction? , 2017, Current diabetes reviews.

[11]  W. Aberer,et al.  Treatment Effect and Safety of Icatibant in Pediatric Patients with Hereditary Angioedema. , 2017, The journal of allergy and clinical immunology. In practice.

[12]  M. C. Lopez-serrano,et al.  An ABC of the Warning Signs of Hereditary Angioedema , 2017, International Archives of Allergy and Immunology.

[13]  A. Kaplan,et al.  Pathogenesis of Hereditary Angioedema: The Role of the Bradykinin-Forming Cascade. , 2017, Immunology and allergy clinics of North America.

[14]  Kenneth H. Lai,et al.  Epidemiology of ACE Inhibitor Angioedema Utilizing a Large Electronic Health Record. , 2017, The journal of allergy and clinical immunology. In practice.

[15]  J. Bernstein,et al.  Angioedema in the emergency department: a practical guide to differential diagnosis and management , 2017, International Journal of Emergency Medicine.

[16]  Dirceu Solé,et al.  Diretrizes brasileiras para o diagnóstico e tratamento do angioedema hereditário - 2017 , 2017 .

[17]  J. Bernstein,et al.  Management of Children With Hereditary Angioedema Due to C1 Inhibitor Deficiency , 2016, Pediatrics.

[18]  T. Machnig,et al.  Efficacy of Different Medical Therapies for the Treatment of Acute Laryngeal Attacks of Hereditary Angioedema due to C1-esterase Inhibitor Deficiency. , 2016, The Journal of emergency medicine.

[19]  K. Bork,et al.  Hereditary angioedema with normal C1‐INH with versus without specific F12 gene mutations , 2015, Allergy.

[20]  I. Jáuregui,et al.  Management of angioedema without urticaria in the emergency department , 2014, Annals of medicine.

[21]  I. Ball,et al.  Prognostic factors in outcome of angioedema in the emergency department. , 2014, Allergy and Asthma Proceedings.

[22]  K. Bork Pasteurized and nanofiltered, plasma-derived C1 esterase inhibitor concentrate for the treatment of hereditary angioedema. , 2014, Immunotherapy.

[23]  M. Triggiani,et al.  Classification, diagnosis, and approach to treatment for angioedema: consensus report from the Hereditary Angioedema International Working Group , 2014, Allergy.

[24]  A. Sheffer,et al.  Abdominal attacks and treatment in hereditary angioedema with C1-inhibitor deficiency , 2014, BMC Gastroenterology.

[25]  C. Camargo,et al.  A consensus parameter for the evaluation and management of angioedema in the emergency department. , 2014, Academic emergency medicine : official journal of the Society for Academic Emergency Medicine.

[26]  W. Aberer,et al.  Open‐label, multicenter study of self‐administered icatibant for attacks of hereditary angioedema , 2014, Allergy.

[27]  J. Bernstein,et al.  Recombinant human C1-esterase inhibitor relieves symptoms of hereditary angioedema attacks: phase 3, randomized, placebo-controlled trial. , 2014, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[28]  M. Triggiani,et al.  Guidance for diagnosis and treatment of acute angioedema in the emergency department: consensus statement by a panel of Italian experts , 2014, Internal and Emergency Medicine.

[29]  M. Scarpellini,et al.  Drug-induced angioedema: experience of Italian emergency departments , 2013, Internal and Emergency Medicine.

[30]  Henry E. Wang,et al.  National estimates of emergency department visits for angioedema and allergic reactions in the United States. , 2013, Allergy and asthma proceedings.

[31]  W. Aberer,et al.  Hereditary Angioedema Attacks Resolve Faster and Are Shorter after Early Icatibant Treatment , 2013, PloS one.

[32]  C. Bethune,et al.  Acute angioedema: recognition and management in the emergency department , 2013, European journal of emergency medicine : official journal of the European Society for Emergency Medicine.

[33]  R. Lockey,et al.  WAO Guideline for the Management of Hereditary Angioedema , 2012, The World Allergy Organization journal.

[34]  K. Bork,et al.  Fatal laryngeal attacks and mortality in hereditary angioedema due to C1-INH deficiency. , 2012, The Journal of allergy and clinical immunology.

[35]  Jay L. Martello,et al.  Ecallantide for treatment of acute attacks of hereditary angioedema. , 2012, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[36]  Tom Bowen,et al.  International consensus and practical guidelines on the gynecologic and obstetric management of female patients with hereditary angioedema caused by C1 inhibitor deficiency. , 2012, The Journal of allergy and clinical immunology.

[37]  T. Machnig,et al.  C1 esterase inhibitor concentrate in 1085 Hereditary Angioedema attacks – final results of the I.M.P.A.C.T.2 study , 2011, Allergy.

[38]  C. Town,et al.  Randomized placebo-controlled trial of the bradykinin B₂ receptor antagonist icatibant for the treatment of acute attacks of hereditary angioedema: the FAST-3 trial. , 2011, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[39]  William H. Yang,et al.  Icatibant, a new bradykinin-receptor antagonist, in hereditary angioedema. , 2010, The New England journal of medicine.